Disc Medicine, Inc. (NASDAQ:IRON) Given Consensus Rating of “Moderate Buy” by Analysts

Disc Medicine, Inc. (NASDAQ:IRON) has received a consensus recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $119.4545.

A number of analysts have recently issued reports on IRON shares. Raymond James Financial reiterated a “strong-buy” rating and issued a $117.00 price objective on shares of Disc Medicine in a report on Monday, December 8th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Wednesday, October 8th. Wells Fargo & Company boosted their price target on shares of Disc Medicine from $91.00 to $109.00 and gave the stock an “overweight” rating in a research report on Tuesday, December 16th. Stifel Nicolaus initiated coverage on shares of Disc Medicine in a research note on Monday, November 3rd. They set a “buy” rating and a $125.00 price objective for the company. Finally, Cowen restated a “buy” rating on shares of Disc Medicine in a report on Friday, December 19th.

Insider Transactions at Disc Medicine

In other news, CEO John D. Quisel sold 40,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was sold at an average price of $93.05, for a total transaction of $3,722,000.00. Following the sale, the chief executive officer owned 171,828 shares in the company, valued at $15,988,595.40. This represents a 18.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, COO Jonathan Yen-Wen Yu sold 30,000 shares of the stock in a transaction that occurred on Tuesday, November 11th. The shares were sold at an average price of $84.70, for a total value of $2,541,000.00. Following the completion of the sale, the chief operating officer directly owned 40,555 shares of the company’s stock, valued at approximately $3,435,008.50. The trade was a 42.52% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders sold 345,895 shares of company stock valued at $31,230,012. 3.64% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of IRON. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Disc Medicine by 22.8% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,138 shares of the company’s stock valued at $756,000 after purchasing an additional 2,807 shares during the period. Millennium Management LLC increased its position in Disc Medicine by 1,277.1% during the first quarter. Millennium Management LLC now owns 108,499 shares of the company’s stock worth $5,386,000 after buying an additional 100,620 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in Disc Medicine by 3.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 96,557 shares of the company’s stock valued at $4,793,000 after buying an additional 3,454 shares during the period. Strs Ohio acquired a new stake in shares of Disc Medicine in the first quarter valued at approximately $347,000. Finally, Rhumbline Advisers boosted its stake in shares of Disc Medicine by 10.7% during the 1st quarter. Rhumbline Advisers now owns 32,144 shares of the company’s stock worth $1,596,000 after acquiring an additional 3,108 shares during the period. 83.70% of the stock is currently owned by institutional investors and hedge funds.

Disc Medicine Price Performance

Shares of NASDAQ IRON opened at $75.44 on Wednesday. The company has a fifty day moving average price of $86.35 and a 200 day moving average price of $72.27. The firm has a market cap of $2.85 billion, a PE ratio of -14.10 and a beta of 0.87. The company has a current ratio of 23.45, a quick ratio of 23.45 and a debt-to-equity ratio of 0.05. Disc Medicine has a 1-year low of $30.82 and a 1-year high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.77) EPS for the quarter, missing analysts’ consensus estimates of ($1.48) by ($0.29). Research analysts predict that Disc Medicine will post -4.07 earnings per share for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.